FDA Approves Novo Nordisk Treatment for Hemophilia

June 5, 2017

The FDA has approved Novo Nordisk’s Rebinyn coagulation treatment for the treatment of adults and children with hemophilia B.

Rebinyn is indicated for treatment and control of bleeding episodes and the perioperative management of bleeding in adults and children with hemophilia B. It is not indicated for routine prophylaxis or for immune tolerance induction in patients with hemophilia B.

Novo Nordisk expects to launch Rebinyn in the first half of 2018.

View today's stories